logo
logo

Procyrion Closes $57.7 Million in Series E Financing

Feb 05, 2024•over 1 year ago

Amount Raised

$57.7 Million

HoustonMedical Equipment Manufacturing

Investors

Undisclosed Strategic InvestorBluebird VenturesFannin Partners

Description

Procyrion, Inc. announced the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing. The funds will be used to support the ongoing DRAIN-HF pivotal IDE trial evaluating the Aortix percutaneous mechanical circulatory support (pMCS) device in patients with acute decompensated heart failure (ADHF) who remain congested despite standard medical therapy (cardiorenal syndrome or CRS), as well as internal programs to improve product manufacturability and prepare for commercialization. The round was led by Fannin Partners in partnership with new and existing family/multi-family office investors.

Company Information

Company

Procyrion, Inc.

Location

3900 ESSEX LANE

Houston, Texas, United States

About

Procyrion is dedicated to improving outcomes for patients with cardiac and renal impairment using its catheter-deployed pump technology to address conditions with significant unmet needs. Aortix™ is a percutaneous mechanical circulatory support device that treats cardiorenal syndrome with a rapidly-deployed intra-aortic catheter-based system.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech